CASI Pharmaceuticals, Inc. (NASDAQ:CASI)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday. They presently have a $2.00 price objective on the biotechnology company’s stock. HC Wainwright’s price target indicates a potential upside of 90.48% from the stock’s previous close.

A number of other equities analysts also recently weighed in on the stock. Maxim Group set a $4.00 target price on shares of CASI Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, May 16th. ValuEngine downgraded shares of CASI Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, July 22nd.

Shares of CASI Pharmaceuticals (NASDAQ:CASI) traded down 4.55% on Friday, hitting $1.05. The stock had a trading volume of 44,418 shares. The firm’s market capitalization is $63.21 million. CASI Pharmaceuticals has a 12-month low of $0.91 and a 12-month high of $1.76. The company has a 50 day moving average of $1.00 and a 200-day moving average of $1.13.

CASI Pharmaceuticals (NASDAQ:CASI) last announced its earnings results on Monday, August 14th. The biotechnology company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by $0.01. Equities analysts predict that CASI Pharmaceuticals will post ($0.15) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “HC Wainwright Reaffirms Buy Rating for CASI Pharmaceuticals, Inc. (CASI)” was published by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.

Receive News & Ratings for CASI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.